Cancer patients who responded to balstilimab can now continue treatment through expanded access

NCT ID NCT05572970

First seen May 14, 2026 · Last updated May 14, 2026

Summary

This expanded access study offers balstilimab alone or combined with zalifrelimab to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who qualify. Participants must have completed the earlier study's requirements.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arizona Oncology Associates

    AVAILABLE

    Tucson, Arizona, 85711, United States

  • Hoag Gynecologic Oncology

    AVAILABLE

    Newport Beach, California, 92663, United States

  • Texas Oncology

    AVAILABLE

    Flower Mound, Texas, 75028, United States

  • The Ohio State University Wexner Medical Center

    AVAILABLE

    Columbus, Ohio, 43212, United States

  • University of Alabama at Birmingham

    AVAILABLE

    Birmingham, Alabama, 35249, United States

  • University of California, San Francisco Medical Center

    AVAILABLE

    San Francisco, California, 94158, United States

  • Women & Infants Hospital of Rhode Island

    AVAILABLE

    Providence, Rhode Island, 02905, United States

Conditions

Explore the condition pages connected to this study.